Removing the bone brake.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25185946.
- Also identified by DOI 10.1016/j.cmet.2014.08.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Osteoporosis results from an imbalance between bone resorption and bone formation. While bone resorption inhibitors are widely used to treat osteoporosis, stimulating bone formation is more challenging. Recently, McClung et al. (2014) found that neutralization of sclerostin, a potent inhibitor of bone formation, effectively increased bone mass in postmenopausal women.
Medical subject headings
- Antibodies, Monoclonal
- Bone Density
- Bone Density Conservation Agents
- Bone Remodeling
- Osteoporosis, Postmenopausal